The company posted a gross profit of E6.2 billion for the fourth quarter of 2011, an increase of 7.5 percent, compared to E5.77 billion for the same period in 2010.
Research and development expenses were E1.29 billion for the fourth quarter of 2011, an increase of 10.7 percent compared to E1.16 billion for the same period in 2010. Selling and general expenses were E2.22 billion for the fourth quarter of 2011, an increase of 0.9 percent, compared to E2.20 billion for the same period in 2010.
For the full year of 2011, net sales were E33.38 billion, an increase of 3.2 percent, compared to E32.36 billion for the same period in 2010. Gross profit was E24.63 billion for the year 2011, a decrease of 0.4 percent, compared to E24.73 billion for the year 2010.
The company posted research and development expenses of E4.81 billion for the year 2011, an increase of 5.6 percent, compared to E4.55 billion for the year 2010. Selling and general expenses were E8.53 billion for the year 2011, an increase of 4.5 percent, compared to E8.17 billion for the year 2010.
Christopher Viehbacher, CEO of the company, said: “2011 was a key year in transforming Sanofi. We successfully acquired and integrated Genzyme, our growth platforms recorded double-digit growth, we delivered cost savings as planned and submitted filings to regulatory authorities for five new products.
“Several product exclusivity losses were absorbed and we successfully limited the impact on business EPS. Beyond the remaining patent cliff in 2012, the robust performance of our diversified growth platforms, the reduced exposure to future patent expiries and progress on R&D, position Sanofi for a period of sustainable growth.”
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.